Essen Amyloidosis Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen
About this trial
The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry aims to improve the understanding of disease progression, diagnostic pathways, and treatment outcomes. The registry is hosted at the University Hospital Essen and follows patients longitudinally. Inclusion is open to all patients with suspected or confirmed amyloidosis who provide informed consent.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Suspected or confirmed amyloidosis (any)
Written informed consent to participate in the study
Age 18 years and above
Disqualifiers
Age < 18 years
Lack of written informed consent
Trial population
All patients with suspected or confirmed amyloidosis treated at the University Hospital Duisburg-Essen are screened for inclusion. A particular focus of the registry lies on amyloid cardiomyopathy and amyloid polyneuropathy.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall mortality or unplanned hospitalization for heart failure
Overall mortality or unplanned hospitalization for heart failure is defined as the primary endpoint. The time to the primary endpoint will be measured in days starting from the day of first diagnosis of cardiac amyloidosis.
Time frame
24 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov